Background Recent reductions in average door-to-balloon (D2B) times have not been associated with decreases in mortality at the population level. We investigated this seemingly paradoxical fi nding by assessing components of this association at the individual and population levels simultaneously. We postulated that the changing population of patients undergoing primary percutaneous coronary intervention (pPCI) contributed to secular trends toward an increasing mortality risk, despite consistently decreased mortality in individual patients with shorter D2B times.
Introduction
Door-to-balloon (D2B) time predicts survival in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). [1] [2] [3] This relation has been thought to be causal, supported by studies in animals 4 and observational evidence 5, 6 indicating that shorter times to reperfusion are linked to decreased myocardial damage and mortality. As a result, clinical guidelines and national quality initiatives in the past decade have focused on shortening D2B times, including the large D2B Alliance sponsored by the American College of Cardiology (ACC) and the Mission:Lifeline Program led by the American Heart Association (AHA). [7] [8] [9] Yet some studies [10] [11] [12] have reported that contemporary decreases in annual D2B times have not been associated with temporal improvements in mortality in the population of patients undergoing pPCI. These unexpected results have raised uncertainty about the value of existing quality initiatives and questions about the true relation between D2B time and mortality. 13 Results from these studies warrant further assessment. The fi ndings have been interpreted, in some quarters, to suggest that a decrease in D2B times do not result in improved outcomes for individual patients. 14, 15 However, for such an assertion to be true the relation between mortality and patient-specifi c D2B times (ie, the D2B time that an individual patient experiences) needs to be disentangled from secular trends in the overall size, profi le, and outcomes of the pPCI population that was simultaneously occurring. The expanded use of the procedure in later years through developing STEMI systems of care could have led to a group of patients with an overall increased risk of survival undergoing the procedure (ie, survivor-cohort eff ect), which might not be fully captured by traditional variables obtained in clinical registries. Although this possibility could mask the eff ects of shorter D2B times on outcomes at the population level, it would not obviate a clinically meaningful relation between D2B times and mortality for an individual patient.
Accordingly, the goal of this study was to unravel the relation between patient-specifi c D2B time and mortality from secular trends in outcomes for the pPCI population. Our hypothesis was that the changing population of patients undergoing pPCI contributed to secular trends toward an increasing mortality risk, despite consistently lower mortality in individual patients with shorter D2B times. With support from the National Cardiovascular Data Registry (NCDR) CathPCI Registry, we included a cohort of patients identical to that of a previous study, 12 but extended this previous work by examining both in-hospital and 6-month mortality outcomes, incorporating more recent data than that used before, and using multilevel models as a principal part of our methods. Multilevel models are invaluable in this setting as they allow for the individual-level relation of D2B times to be examined in the context of broader changes at the population level, and to study both these associations separately. 16, 17 By providing access to the same data sources, this study also represents an open science approach by the NCDR programme by allowing other investigators to build on important issues raised by a previous publication using the same data source.
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Methods
Data sources and study sample
We obtained data sources from the NCDR CathPCI Registry, co-sponsored by the American College of Cardiology (ACC) and the Society for Cardiovascular Angiography and Interventions (SCAI). The NCDR CathPCI Registry is the largest national registry of patients undergoing PCI in the USA, with a rapid doubling in participation from about 600 hospitals in 2005 to over 1400 hospitals by 2011. 19 Although large, participation of hospitals in the NCDR CathPCI Registry is done voluntarily and, therefore, not population-based. The NCDR CathPCI Registry employs trained personnel who obtain detailed information on patient and hospital characteristics, coronary angiographic and procedural fi ndings, and outcomes using standardised data elements-a process overseen by an established data-quality programme. 20 The data-quality programme attempts to ensure that data submitted are complete, consistent, and accurate. Every year, 25 sites are selected randomly for a comprehensive on-site data audit. Because PCI practices change quickly, several registry modifi cations have occurred over time, with recent versions including well over 200 data fi elds. Defi nitions and specifi cations for these data fi elds are available online. Data in the NCDR CathPCI Registry are recorded up to the time of hospital discharge, with long-term follow-up unavailable, which is a potential limitation.
For this study, we looked for catheterisation laboratory visits associated with STEMI. We excluded patients not undergoing pPCI, transfer patients for pPCI, patients with D2B times less than 15 min or more than 3 h (to focus on patients who had the most gain with myocardial salvage), and patients at hospitals that did not consistently report data across the study period. This selection process created a pPCI population for analysis and was identical to that used to create a cohort from the most recent study 12 to assess this question. No patients were excluded for non-system delays unlike current accountability measures. We noticed variations in these selection criteria over time that were associated with expansion of STEMI systems of care nationally. For example, the proportion of patients undergoing pPCI out of the total PCIs at a hospital grew from 4·3% in 2005 to 6·8% in 2011, and non-transfer patients grew from 62·3% to 78·3% of all pPCIs. The Institutional Review Board at Yale University granted us a waiver to use de-identifi ed data and provided authorisation for this study.
Study variables
We calculated patient-specifi c D2B times for every case and then used them to determine annual D2B times at the population level for every year. Patient-specifi c D2B times were based on data from catheterisation laboratory visits and defi ned as the time from hospital arrival to fi rst device use during pPCI (eg, balloon or thrombectomy catheter). We identifi ed annual D2B times by calculating the median of patient-specifi c D2B times during the year the procedure was done in the pPCI population. We examined both in-hospital and 6-month mortality. We obtained all-cause in-hospital mortality from the NCDR CathPCI Registry, and we assessed 6-month mortality in a group of patients aged 65 years or older in the NCDR CathPCI Registry who had been successfully matched to fee-for-service (FFS) claims data available from the Centers for Medicare & Medicaid Services (CMS) between 2005 and 2011, consistent with previous work. 12 The process of matching, and its success and generalisability has been previously reported. 21 Generally, about 75% of eligible procedures can be linked to patients within the CMS claims data, with similar patient characteristics noted between linked and unlinked individuals.
An extensive list of patient and procedural factors related to the pPCI were available from the NCDR Cath PCI Registry for risk adjustment (appendix). Missing data were rare for most variables (<1%) with the exception of ejection fraction (about 25%) and glomerular fi ltration rate (about 8% of creatinine assessments before and after procedure). In both cases, values for these variables were imputed for missing data through a standardised approach used in previous studies 22 including the NCDR CathPCI Registry.
Statistical analysis
We compared baseline demographic and clinical characteristics of patients undergoing pPCI across years. For these analyses, we defi ned 7 years in the study period: 2005, 2006, 2007, 2008, 2009, 2010 , and 2011. We compared continuous variables across years using analysis of variance and categorical variables with the χ² test. We plotted the annual D2B time in the pPCI population against unadjusted in-hospital mortality for each year to examine the population-level relation across years. Next, we plotted patient-specifi c D2B times (grouped by deciles) against unadjusted in-hospital mortality within each of the periods to examine the individual patient-level relation within years. Fitted linear trend lines were used to aid with visual comparison.
We then built multilevel logistic regression models to estimate both individual and population-level components of the association between D2B time and mortality, after accounting for diff erences in recorded patient and procedural factors. Models simultaneously included as predictors of mortality, the patient-specifi c D2B time (ie, the D2B time the individual patient experienced), and the annual D2B time (ie, the median D2B time in the year in which the PCI for that patient was done). Neither of these variables was centred before inclusion. The coeffi cient estimate for patient-specifi c D2B time represented the individual-level relation between D2B time and mortality after accounting for other factors, including annual D2B time. The coeffi cient estimate for annual D2B time represented the population-level relation or secular trend between decreasing average D2B time and mortality after accounting for other factors, such as patient-specifi c D2B time. We also constructed models that only included annual D2B time for every patient. The coeffi cient estimate for annual D2B time obtained from this model represented the aggregate relation that consisted of both the individual and population-level relations of D2B time.
Patient and procedural factors included within the models for risk-adjustment were those from the published NCDR CathPCI mortality risk model for PCI. 22 We included random intercepts for each hospital to account for the clustering eff ects of procedures within hospitals. We built analogous models for both in-hospital and 6-month mortality. We generated odds ratios (ORs) and 95% CIs for mortality for reporting. For patient-specifi c D2B times, we reported these ORs as a change per 10 min decrease whereas we reported annual D2B time as a change per year. We used the SAS software version 9.2 (Cary, NC, USA) for all analyses. We used the SAS GLIMMIX procedure for all analyses related to the multilevel models.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. BKN, YW, and HMK had full access to all the data in the study, and all authors had fi nal responsibility for the decision to submit for publication.
Results
Study sample
For this study, we identifi ed 512 321 catheterisation laboratory visits associated with STEMI between Jan 1, 2005, and Dec 31, 2011. We excluded patients not under going pPCI (n=52 372), transfer patients for pPCI (n=129 579), patients with D2B times less than 15 min or . Overall, unadjusted in-hospital mortality was 4·7% in the total cohort and unadjusted 6-month mortality was 13·5% in the cohort of patients aged 65 years or older (table 1) . During this time period, risk-adjusted in-hospital mortality rose non-signifi cantly (from 4·7% to 5·3%; p=0·06) whereas risk-adjusted 6-month mortality increased signifi cantly (from 12·9% to 14·4%; p=0·001). Table 1 shows a full list of patient and procedural factors, stratifi ed by year. We noted signifi cant, but modest diff erences across years in several demographic features (eg, age >75 years) and clinical features (eg, diabetes mellitus, history of PCI, and New York Heart Association [NYHA] Class IV status) in the pPCI population.
Treatment patterns associated with pPCI also diff ered signifi cantly across years with some large diff erences noted. We also noted a substantial increase in the total number of patients treated every year at these 423 hospitals: overall, 55% more patients underwent pPCI in Rates of direct thrombin inhibitor use increased more than four-fold from 10% to 42% and manual thrombectomy use rose from 12% to 39%, whereas use of glycoprotein IIb/IIIa dropped from 73% to 45%, and drug-eluting stent use dropped from 76% to 53% (table 1) .
The individual-level relation between D2B times and mortality showed that decreases in patient-specifi c D2B times were consistently associated with decreased In-hospital mortality 6-month mortality Adjusted OR p value Adjusted OR* p value
Patient-specifi c D2B times (per 10 min decrease)
Annual D2B times (per 1 year change)
OR=odds ratio. D2B=door-to-balloon. *Adjusted for patients characteristics within the NCDR CathPCI Risk Model. Table 2 : Relation between patient-specifi c D2B time, annual D2B time, and mortality in-hospital mortality within each year of the study period (fi gure 1). The population-level relation showed little correlation between decreases in annual D2B times and mortality across years. Additionally, an increase in mortality was noted across years, as the fi tted linear trend lines are generally higher during later years, and predominately diverge during later deciles of patient-specifi c D2B times. For example, the last decile of patient-specifi c D2B times in 2005, was 154 min with an unadjusted in-hospital mortality of 8·1% whereas the last decile of patient-specifi c D2B times in 2011, was 127 min with an unadjusted in-hospital mortality of 11·0% (fi gure 1). Lastly, longer delays in patient-specifi c D2B time were associated with increasing mortality over the years of the study. For example, patients with D2B times longer than 90 min had an in-hospital mortality of 6·1% in 2005 and of 10·3% in 2011. Table 2 displays results of estimates from the multilevel models that simultaneously examined associations between D2B time and mortality at the individual patient level and the population level (the appendix shows full model results that include all of the variables accounted for during risk-adjustment; the c-statistics for the models for in-hospital mortality were 0·893 and for 6-month mortality 0·812). Adjusted for observed patient and procedural factors and population D2B times, reduced patient-specifi c D2B times over the study period were consistently associated with reduced in-hospital mortality and 6-month mortality (table 2, fi gure 2). However, decreases in annual D2B times were associated with increased risk-adjusted in-hospital mortality and signifi cantly higher 6-month mortality, representing worsening mortality risk across years of the study period (table 2). Figure 3 displays secular trends in predicted in-hospital and 6-month mortality for the pPCI population across years, keeping all other covariates constant, including patient-specifi c D2B times. In models that only included annual D2B time for every patient, we found that the aggregate relation (comprised of both the individual and population-level relations of D2B time) suggested no association with either in-hospital mortality (0·99; 95% CI 0·96-1·02; p=0·54) or 6-month mortality (0·99; 0·96-1·03; p=0·78).
Discussion
Previous studies linked a decrease in patient-specifi c D2B times with a decrease in mortality after pPCI at the individual level. However, recent decreases in annual D2B times at the population-level have not been associated with decreases in mortality as predicted (panel). The purpose of this study was to off er additional insights on this seemingly paradoxical fi nding and its implications for STEMI care. Through multilevel models, which simultaneously estimated both the individual and population-level components of the association of mortality with D2B time, we uncovered several key fi ndings. First, we confi rmed that recent decreases in annual D2B times at the population level have occurred during a period at which no associated improvement in in-hospital mortality occurred. In fact, using more contemporary data and extended follow-up, we found these changes in annual D2B times occurred during a period of rising risk-adjusted in-hospital and 6-month mortality in the pPCI population. However, we also showed that shorter patient-specifi c D2B times are strongly and consistently associated with lower risk-adjusted in-hospital and 6-month mortality at the individual level. So why have anticipated decreases in mortality over time not occurred in the pPCI population despite reductions in annual D2B time and a consistent association between patient-specifi c D2B time and outcomes? The results of this study suggest that the most likely explanation is expanding use of pPCI and the changing population of patients with STEMI undergoing the procedure. This is supported by the fi nding that the annual number of pPCIs reported within this stable cohort of hospitals increased by more than 50% between 2005 and 2011-a period during which estimates of pPCI use grew from 40% to 80% of patients with STEMI in the USA, 28, 29 whereas STEMI incidence decreased nationally. 30 Additionally, we noted that several patient and procedural factors varied across years, with unobserved factors potentially modifying patient case-mix as well. For example, manual aspiration thrombectomy and bivalirudin use increased by roughly four times in the pPCI population during this study period, and whether (or how) these changes aff ected outcomes as is unclear since clinical trials of these therapies have reported mixed results. 31, 32 Lastly, we noted increasing mortality over the study period in patients with the longest D2B times. We postulate that some of these patients might have not reached the cardiac catheterisation laboratory in earlier years when STEMI systems of care were less common, a phenomenon Terkelsen and colleagues 33 have referred to as the survivor-cohort eff ect. Thus, the increased mortality of this high-risk cohort might off set gains in patients with shorter D2B times.
These fi ndings have several implications for patients and the cardiology community. The results caution against misinterpretation of the absence of association between decreasing annual D2B times and mortality at a population level as evidence that improvements in patient-specifi c D2B time have not aff ected mortality at an individual level. Such an interpretation, as asserted in some recent discussions on the topic, 14, 15 confl ates so-called micro-level and macro-level associations, which is an ecologic fallacy. 34 The multilevel models used in this study address these concerns by allowing both types of associations to be modelled simultaneously to generate better inferences for each. As such, this study helps clarify that shorter patient-specifi c D2B times are associated with lower mortality at the individual level, after accounting for secular trends toward higher mortality overall in the pPCI population over time (as use of the procedure changed in later years). We believe this fi nding continues to lend support to ongoing quality improvement initiatives that target minimising time-to-treatment in the hospital, and point toward the importance of a reduction in total ischaemic time through other system delays.
Additionally, this study highlights the importance of an open science approach and reproducible research, a growing movement in other fi elds that is also gaining traction in medicine. 35 We had the opportunity to do these analyses because of access to the same data sources used in a previous study also supported by the NCDR CathPCI Registry. 12 This access allowed us to build on the earlier work using more years of data and long-term outcomes. However, it also eliminated the possibility that diff erences in the fi ndings we report here merely portrayed variability in data collection methods, study populations, or health-care systems. These same data sources were made available to us from the NCDR CathPCI Registry with funds also provided to perform these additional analyses. The process itself shows the value of a collaborative research framework that is aimed to advance scientifi c progress through an iterative process for the ultimate benefi t of patients and clinicians.
The study fi ndings should be interpreted with the following limitations in mind. First, the inference of a causal relation between shorter patient D2B times and
Panel: Research in context
Systematic Review
We previously reviewed data for door-to-balloon time in primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). 6 We updated our review of this topic with a more contemporary Medline search using the search terms "door-to-balloon time" and "mortality". Generally, we found that longer door-to-balloon times have been correlated with worse outcomes in several, but not all, reports that have used observational data. Many reports [23] [24] [25] [26] [27] have suggested that delays might be most important early after symptom onset (eg, within fi rst 2-3 h) or in high-risk patients (eg, cardiogenic shock). Others 11 have raised the issue that worse outcomes due to delays might largely result from confounding-that is, high-risk patients need stabilisation and have longer door-to-balloon times than do low-risk patients. In this context, a recent study suggested that contemporary decreases in annual D2B times in the population undergoing primary PCI have not been associated with temporal improvements in mortality. 12 This population-level association has been construed as suggesting shorter door-to-balloon times in individual patients have not improved care-a potential misinterpretation consistent with an ecological fallacy.
Interpretation
The goal of this retrospective study was to unravel the association between D2B time and mortality at both the population level and individual level simultaneously. We postulated that the changing population of patients contributed to secular trends toward an increasing mortality risk, despite consistently lower mortality in individual patients with shorter D2B times. For this study, we used data between Jan 1, 2005, and Dec 31, 2011, in the National Cardiovascular Data Registry (NCDR) CathPCI Registry. By contrast with the recent study discussed above that examined contemporary reductions in annual D2B times at the population level only, we built multilevel models to assess the relation between D2B time and in-hospital and 6-month mortality that included both individual and population-level components of this association. Overall, our fi ndings revealed that shorter D2B times were consistently correlated with lower mortality at the individual level within every year of our study period, whereas secular trends suggested an increased mortality risk over time at the population level. Thus, the absence of association of annual D2B time and changes in mortality at the population level should not be interpreted as an indication of its individual-level relation in patients with STEMI undergoing primary PCI.
lower mortality cannot be proven conclusively by this study, or any other study based on observational data. However, the individual-level relation we noted lends support to the causal hypothesis that ischaemia time aff ects outcomes. Additional work will be needed to examine how this relation extends to other key components of total ischaemia time, such as time from symptom onset to fi rst medical contact, and use of pre-hospital electrocardiography and emergency medical services. All of these areas are logically becoming the next stage for focus as D2B times have dropped substantially in recent years and recognition of the importance of system delay has grown. 33 Second, the risk-adjustment methods we used have several limitations, some of which, in fact, might help explain the seemingly paradoxical results we discuss. We used the NCDR PCI risk model to be consistent with a previous study, 12 but this risk model was developed in a broad population of patients that mainly included non-emergent PCI. 22 It might not capture all the patient and procedural factors that changed in the pPCI population over time, and more recent models have been developed incorporating better variable defi nitions around high-risk patients. We unfortunately could not use these newer models as such information was inconsistently available over the study period.
Third, these hospitals that consistently participated in the NCDR CathPCI Registry over this study period might not be representative of all hospitals performing PCI either in the USA or worldwide, although we have no reason to suspect that the clinical association between D2B time and outcomes would diff er for patients at these centres. Fourth, we provide data only until 2011 even as the use of pPCI continues to grow. Fifth, evidence exists that the relation between time-to-treatment and outcomes in STEMI is non-linear with benefi ts of reperfusion diminishing over time. 36, 37 Estimation of per-minute survival benefi ts made directly from our data and over a broad range of delays should be done cautiously.
Finally, this study cannot determine all of the specifi c reasons for rises in in-hospital mortality or 6-month mortality for the pPCI population over time. The results indicate, however, expansion in the pPCI population and substantial changes in treatment and patient characteristics over time. The population-level trend in outcomes therefore should not be taken as evidence against the clinical benefi ts of pPCI, as established in clinical trials. 38 The expanded use of pPCI in later years in a larger number of patients with STEMI, particularly in the USA, indicates its use in those who would have previously received fi brinolysis or no reperfusion therapy with a potentially increased risk for worse outcomes. However, we cannot comment on whether this policy is appropriate or eff ective for a population, especially where resources required for pPCI might diff er and alternative therapeutic options exist (eg, pharmacoinvasive strategy with fi brinolytic therapy followed by non-emergent PCI).
In conclusion, we noted that decreases in D2B times were consistently associated with decreases in in-hospital and 6-month mortality in patients with STEMI undergoing pPCI. However, mortality has not decreased and might even be increasing over time in the growing subset of patients with STEMI undergoing pPCI, despite reductions in annual D2B time. This fi nding seems to indicate secular trends in the pPCI population toward increased mortality risk in later years that coincides with expansion in the use of the procedure during STEMI, as well as changes in patient and procedural factors. These fi ndings highlight the importance of continued vigilance with D2B times and caution against misinterpretation of the absence of association between annual D2B time and changes in mortality at the population level as an indication of its individual-level relation in patients with STEMI.
